F
Frederic Brosseron
Researcher at German Center for Neurodegenerative Diseases
Publications - 55
Citations - 6177
Frederic Brosseron is an academic researcher from German Center for Neurodegenerative Diseases. The author has contributed to research in topics: Cognitive decline & Medicine. The author has an hindex of 14, co-authored 37 publications receiving 4059 citations. Previous affiliations of Frederic Brosseron include University Hospital Bonn.
Papers
More filters
Journal ArticleDOI
Neuroinflammation in Alzheimer's disease
Michael T. Heneka,Monica J. Carson,Joseph El Khoury,Gary E. Landreth,Frederic Brosseron,Douglas L. Feinstein,Andreas H. Jacobs,Tony Wyss-Coray,Tony Wyss-Coray,Javier Vitorica,Richard M. Ransohoff,Karl Herrup,Sally A. Frautschy,Bente Finsen,Guy C. Brown,Alexei Verkhratsky,Alexei Verkhratsky,Alexei Verkhratsky,Koji Yamanaka,Jari Koistinaho,Eicke Latz,Eicke Latz,Annett Halle,Gabor C. Petzold,Terrence Town,Dave Morgan,Mari L. Shinohara,V. Hugh Perry,Clive Holmes,Clive Holmes,Nicolas G. Bazan,David J. Brooks,Stéphane Hunot,Bertrand Joseph,Nikolaus Deigendesch,Olga Garaschuk,Erik Boddeke,Charles A. Dinarello,John C.S. Breitner,Greg M. Cole,Douglas T. Golenbock,Markus P. Kummer +41 more
TL;DR: Genome-wide analysis suggests that several genes that increase the risk for sporadic Alzheimer's disease encode factors that regulate glial clearance of misfolded proteins and the inflammatory reaction.
Journal ArticleDOI
NLRP3 inflammasome activation drives tau pathology
Christina Ising,Carmen Venegas,Shuangshuang Zhang,Hannah Scheiblich,Susanne V. Schmidt,Ana Vieira-Saecker,Stephanie Schwartz,Shadi Albasset,Róisín M. McManus,Dario Tejera,Angelika Griep,Francesco Santarelli,Frederic Brosseron,Sabine Opitz,James Stunden,Maximilian Merten,Rakez Kayed,Douglas T. Golenbock,David Blum,Eicke Latz,Eicke Latz,Eicke Latz,Luc Buée,Michael T. Heneka,Michael T. Heneka +24 more
TL;DR: An important role of microglia and NLRP3 inflammasome activation in the pathogenesis of tauopathies is identified and the amyloid-cascade hypothesis in Alzheimer’s disease is supported, demonstrating that neurofibrillary tangles develop downstream of amyloids-beta-induced microglial activation.
Journal ArticleDOI
sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers
Marc Suárez-Calvet,Marc Suárez-Calvet,Gernot Kleinberger,Miguel Ángel Araque Caballero,Matthias Brendel,Axel Rominger,Daniel Alcolea,Juan Fortea,Alberto Lleó,Rafael Blesa,Juan Domingo Gispert,Raquel Sánchez-Valle,Anna Antonell,Lorena Rami,José Luis Molinuevo,Frederic Brosseron,Andreas Traschütz,Michael T. Heneka,Michael T. Heneka,Hanne Struyfs,Sebastiaan Engelborghs,Kristel Sleegers,Christine Van Broeckhoven,Henrik Zetterberg,Henrik Zetterberg,Bengt Nellgård,Kaj Blennow,Alexander Crispin,Michael Ewers,Christian Haass,Christian Haass +30 more
TL;DR: CSF sTREM2 levels are increased in the early symptomatic phase of AD, probably reflecting a corresponding change of the microglia activation status in response to neuronal degeneration.
Journal ArticleDOI
Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer’s Disease: a Comparative Overview
TL;DR: A comprehensive overview of cytokine and other inflammation associated protein levels in plasma, serum and cerebrospinal fluid of patients with Alzheimer’s disease (AD) and mild cognitive impairment (MCI) is given.
Journal ArticleDOI
Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
Frank Jessen,Frank Jessen,Annika Spottke,Annika Spottke,Henning Boecker,Henning Boecker,Frederic Brosseron,Katharina Buerger,Katharina Buerger,Cihan Catak,Klaus Fliessbach,Klaus Fliessbach,Christiana Franke,Manuel Fuentes,Michael T. Heneka,Michael T. Heneka,Daniel Janowitz,Ingo Kilimann,Ingo Kilimann,Christoph Laske,Christoph Laske,Felix Menne,Peter J. Nestor,Oliver Peters,Josef Priller,Verena Pross,Alfredo Ramirez,Alfredo Ramirez,Anja Schneider,Anja Schneider,Oliver Speck,Eike Jakob Spruth,Stefan J. Teipel,Stefan J. Teipel,Ruth Vukovich,Christine Westerteicher,Christine Westerteicher,Jens Wiltfang,Jens Wiltfang,Jens Wiltfang,Steffen Wolfsgruber,Steffen Wolfsgruber,Michael Wagner,Michael Wagner,Emrah Düzel +44 more
TL;DR: The initial baseline data for DELCODE support the approach of using SCD in patients recruited through memory clinics as an enrichment strategy for late-stage preclinical AD.